


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+9.60%
-9.82%
-1.00%
-0.49%
+1.01%
HRMY
Harmony Biosciences
$40.51
Strengths

Upgraded on attractively valued

Earnings are forecast to grow
HRMY Price Performance
$33.99 (+19.18%)
$32.54 (+24.49%)
$36.71 (+10.35%)
$34.2 (+18.45%)
HRMY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

HRMY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
HRMY Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
HRMY Street Sentiment is bullish and have negative views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is HRMY current stock price?
What are HRMY stock strengths?
What is HRMY Risk Level?
What is HRMY market cap and volume?
What is HRMY current Stock IQ?
Should I buy HRMY stock right now?
Is HRMY a Strong Buy right now?
What does a 'Strong Buy' rating mean for HRMY?
What does a 'Strong Sell' rating mean for HRMY?
What factors influence HRMY's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+9.60%
-9.82%
-1.00%
-0.49%
+1.01%
HRMY
Harmony Biosciences
Current Price
$40.51
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

HRMY Price Performance
$33.99 (+19.18%)
$32.54 (+24.49%)
$36.71 (+10.35%)
$34.2 (+18.45%)
HRMY Analysts Opinion
HRMY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Reported a strong earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
HRMY Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
HRMY Street Sentiment is bullish and have negative views on the near-term outlook
HRMY has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
HRMY Stock IQ
HRMY Latest Analysis
Harmony Biosciences To Present New Data From Phase 3 Trial Of EPX-100 In Dravet Syndrome Next Week . (RTTNews) - Harmony Biosciences Holdings Inc. (HRMY) is set to highlight new open-label extension data from its ongoing ARGUS trial at the American Epilepsy Society Annual Meeting on December 8 2025.
Wed Dec 3, 2025
Needham Reiterates Harmony Biosciences Holdings (HRMY) Buy Recommendation. Fintel reports that on November 24 2025 Needham reiterated coverage of Harmony Biosciences Holdings (NasdaqGM:HRMY) with a Buy recommendation. Analyst Price Forecast Suggests 35.40% Upside
Tue Nov 25, 2025
HC Wainwright & Co. Reiterates Harmony Biosciences Holdings (HRMY) Buy Recommendation. Fintel reports that on November 24 2025 HC Wainwright &. Co. reiterated coverage of Harmony Biosciences Holdings (NasdaqGM:HRMY) with a Buy recommendation. Analyst Price Forecast Suggests 35.40% Upside
Tue Nov 25, 2025
Harmony Biosciences Reports Positive Results For Pitolisant GR. Plans NDA Filing In Early 2026 . (RTTNews) - Harmony Biosciences Holdings Inc. (HRMY) said Monday that a pivotal bioequivalence (BE) study of its pitolisant gastro-resistant (GR) formulation showed that 17.8 mg of pitolisant GR is bioequivalent to the currently marketed 17.8 mg pitolisant tablet.
Mon Nov 24, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
HRMY Stock trends
HRMY Stock performance
HRMY Stock analysis
HRMY investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.